Our investigational BCL2 inhibitor was recently granted Fast Track Designation by the FDA for relapsed/refractory Waldenström macroglobulinemia (#WM), recognizing the potential for this next-generation compound to address significant unmet need. Read more about WM and how we are leading with science to advance innovative #oncology medicines for patients: https://bit.ly/3x2LVeW
Parabéns
Fantastic!! 👏
Machine Learning Engineering Manager
4wProfessor Mobasher has been one of the most inspirational figures in the field. Glad he is on the forefront of drug discovery.